Ticker: TEM
Tempus AI
Healthcare
Healthcare
Medical - Healthcare Information Services
Price
58.74
Reco
Hold
Potential
69
Risk
66
Updated
2026-09-10
Forecast impact
Target
+24.0%
target fill 80.6%
Reaction
D5 +1.39% · D10 pending
fresh confirmed
· market trust
Impact
Potential +6 · Risk -3
valid until 2026-10-01
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
Description
Company and Business Model
Tempus AI operates in the healthcare sector, focusing on data-driven solutions for precision medicine. Its core products include genomic sequencing, clinical data analysis, and AI-driven insights aimed at improving patient outcomes. Major business segments encompass oncology, cardiology, and rare diseases, with primary revenue sources stemming from partnerships with healthcare providers and pharmaceutical companies.
Investment Profile
The investment profile of Tempus AI is more aligned with growth investors, given its focus on innovative healthcare solutions and potential market expansion. However, the high risk associated with its current performance metrics suggests caution. The stock may appeal to those with a medium to long-term horizon, seeking exposure to advancements in healthcare technology.
Fundamental metrics (experimental) Updated: 2026-09-06
- EPS (TTM) — earnings per share for the last 12 months, $
- -1.43
- Revenue QoQ — quarter-over-quarter revenue growth
- 9.9%
- EPS surprise
- 72.0%
- 20d volatility
- 7.0%
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-10 | Buy | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-09-05 | Hold | Buy | Strong revenue growth and positive EPS surprise indicate potential. |
| 2026-08-29 | Buy | Hold | High volatility and negative momentum raise concerns. |
| 2026-08-21 | Hold | Buy | Strong momentum and positive earnings surprise support growth outlook. |
| 2026-08-12 | Sell | Hold | Strong revenue growth and positive EPS surprise indicate potential. |
| 2026-07-08 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-29 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-05-08 | — | Sell | scenario_deterioration |
| 2026-05-05 | Sell | Hold | Компания показывает положительную динамику выручки и краткосрочный рост, однако отрицательный EPS и значительное падение за 120 дней указывают на высокие риски. |
| 2026-04-27 | Hold | Sell | Компания демонстрирует значительное снижение цены за последние 120 дней и отрицательный EPS, что указывает на высокие риски. Несмотря на положительные показатели роста выручки, общая динамика акций вызывает опасения. |
| 2026-04-19 | Sell | Hold | Компания показывает сильный рост за последние 5 дней, но имеет отрицательный EPS и значительное падение за последние 120 дней, что указывает на высокие риски. |
| 2026-03-19 | Hold | Sell | scenario_deterioration |
| 2026-03-11 | Sell | Hold | Компания демонстрирует значительное снижение цен на акции за последние 60 и 120 дней, а также отрицательный EPS, что указывает на высокие риски и низкий потенциал роста. |
| 2026-02-26 | Hold | Sell | Компания демонстрирует значительное снижение цен на акции и отрицательный EPS, что указывает на финансовые проблемы. Рынок также показывает высокую волатильность, что увеличивает риск инвестиций. |
| 2026-02-20 | — | Hold | Компания показала сильный рост за последний день и неделю, однако долгосрочные показатели указывают на снижение. Рекомендуется держать акции до прояснения ситуации. |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-09 | UBS | Update | — → 70 | 64.29 |
| 2026-09-08 | Redburn Partners | Update | — → 67 | 64.62 |
| 2026-09-02 | Raymond James | Update | — → 80 | 62.27 |
| 2026-09-02 | Cantor Fitzgerald | Update | — → 80 | 62.27 |
| 2026-09-01 | Piper Sandler | Rating Upgraded | — → 76 | 63.05 |
| 2026-08-04 | Piper Sandler | Target Lowered | 58 → 56 | 46.05 |
| 2026-08-03 | BTIG | Target Lowered | 80 → 70 | 46.7773 |
| 2026-08-03 | H.C. Wainwright | Target Lowered | 64 → 56 | 46.95 |
| 2026-08-03 | Stifel Nicolaus | Target Lowered | 60 → 50 | 43.87 |
| 2026-07-16 | Guggenheim | Target Raised | — → 65 | 57.25 |
| 2026-05-11 | H.C. Wainwright | Target Lowered | 95 → 64 | 49.86 |
| 2026-05-10 | BTIG | Target Lowered | 90 → 80 | 49.86 |
| 2026-03-10 | H.C. Wainwright | Target Raised | — → 95 | 52.0271 |
| 2026-02-25 | Stifel Nicolaus | Target Lowered | — → 60 | 53.83 |
| 2026-02-19 | Mizuho Securities | Update | — → 100 | 56.16 |
| 2026-02-17 | Robert W. Baird | Update | — → 59 | 51.95 |
| 2025-12-22 | Canaccord Genuity | Target Lowered | 95 → 80 | 64.46 |
| 2025-12-01 | Morgan Stanley | Update | — → 85 | 74.07 |
| 2025-11-25 | BTIG | Target Raised | — → 105 | 76.06 |
| 2025-11-05 | Canaccord Genuity | Target Lowered | — → 95 | 84.49 |
News Page 1 of 1
Nothing yet